An observational study in Malaria, Pneumocystis, Leishmania, sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia · Observational
The goal is to develop molecular systems to support or replace in microscopic characterization and in vitro tests with molecular biology systems capable of improving performance in parasitology tests. In particular, we will analyze the main pathogens: several Leishmania species (Old and New World Leishmania species), the five Plasmodium species of human interest (falciparum, oval, vivax, malariae and knowlesi) and Pneumocistys jiroveci, using molecular methods based on the speed, specificity and sensitivity necessary for their diagnosis. Furthermore, we want to provide specific elements for the typing of the species. Our aim is to improve diagnostic and specie classification methods by using PCR in microbiology and parasitology, to evaluate its impact on diagnosis. We would evaluate the impact of this method in terms of timing, sensitivity and specificity of diagnosis. We would also explore future possibilities on quantification techniques, in order to support the clinician to evaluate the efficacy of therapy during the follow-up.
Furthermore, we would evaluate these methods in terms of cost effectiveness towards classical direct methods, which are now operator-dependent.
Our project is an observational retrospective and prospective cross-sectional diagnostic pilot study, about the comparison between standard routine laboratory tests and new molecular biology assays. In particular, we would detect principal pathogen Leishmania species (Old and New World Leishmania species), the five species of Plasmodium of human interest (falciparum, oval, vivax, malaria and knowlesi) and Pneumocistys jiroveci,
1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.
This study's planned enrollment of 200 is below the median of 582 across 204 observational studies indexed under Malaria.
Browse Malaria studies →Fondazione IRCCS Policlinico San Matteo di Pavia is the lead sponsor of 258 studies on the registry; 115 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Positive samples for Leishmania amastygotes in peripheral blood and/or bone marrow aspirate/biopsy and/or from cutaneous scraping/biopsy previously tested according to routine diagnostic assays 2-Plasmodium species blood positive samples tested for and analyzed by direct microscopy and immunocromatographic assay, 3-Pneumocistis jirovecii in positive BAL or bronchoaspirate (BAS) samples obtained by direct microscopy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Approximately 200-300 samples retrospectively submitted to the laboratory for the study in question, for the detection of P. jirovecii, Plasmodium Malaria and Leishmania tested with the classical method.
Exclusion Criteria:
Samples that are unsuitable due to storage errors and/or insufficient volume will be excluded.
Pneumocystis PCR test
Primary endpoint will be the estimation of sensitivity of PCR tests in identifying the presence of main pathogens: Leishmania species, Plasmodium species and Pneumocistys jiroveci.
Time frame: From January 2024 to september 2025
Malaria PCR test
Secondary endpoint will be the comparison of the concentration of P. falciparum DNA in blood samples (measured by qPCR) according to parasitemia (\>5% vs \<5%).
Time frame: From genuary 2025 to september 2026
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2023 (actual). Primary completion is estimated for Sep 2026, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS Policlinico San Matteo di Pavia →